Positive Results From Phase III Study For Lebrikizumab; Almirall Will Seek Commercial Authorisation
Bankinter | Lebrikizumab is a new treatment being developed for atopical dermatitis licensed by Eli Lilly to Almirall (ALM). In the third study in Phase III, it has shown to have had a significant improvement on the skin, relieving itching for people with this ailment when combined with topical corticosteroids. The study has met all the primary valuation criteria and the principal secondary ones, and has a security profile consistent…